NAVIGATION
    • Home
    • Decision Support & Diagnostic Aids

Decision Support Tools & Diagnostic Aids

Decrease time and cost for diagnosis

Decision Support & Diagnostic Aids

Decision Support

Crosswalk Insight™: Oncology for Precision Medicine

A precision medicine knowledge visualization and decision support tool, Crosswalk connects users to information about cancer disease types through tumor images, biomarkers, molecular pathways, and the relevant FDA-approved drugs and clinical trials.

Crosswalk is both a precision medicine knowledge base and graphical user interface for knowledge visualization, “just-in-time” learning and biomedical decision support.

Crosswalk contains integrated information on cancer diagnosis and treatment organized in the following four categories:

  • Tumors include 36 solid tumor types and subtypes and selected hematologic malignancies
  • Biomarkers include 68 macromolecular entities that represent clinically actionable drug targets and diagnostic or prognostic biomarkers
  • Pathways include 22 signaling pathways or biological processes that provide the mechanistic context for carcinogenesis, molecular diagnostics and phamacotherapies
  • Drugs include 68 FDA-approved targeted and immune-therapies for 36 tumor types and companion diagnostics

crosswalk-diagram-e1473348518759

Tumors are accompanied by images of typical microscopic morphology, textual descriptions of clinical significance and histopathologic and molecular features with supporting literature citations in selected bibliographies of recent publications linked to PubMed.gov.

Biomarkers are illustrated by 3D renderings of protein structures, annotated with key features such as drug-binding sites and the locations of pathogenic variants/mutations. Biomarkers for which no structural information is available are represented by protein-protein interaction networks. Beyond the 68 “front-page” genes and proteins, information on an additional 124 genes and proteins involved in cancer biology is included in relevant contexts. Textual and bibliographic information is included for tumors.

Pathways are rendered as diagrams, focusing on key nodes and processes, and sites of drug action. Each diagrammatic entity is hyperlinked to related information in the knowledge base. Textual and bibliographic information are included.

Drugs include generic and brand names, images of the actual tablets, capsules, vials and/or packaging, the chemical or protein structures of small molecule drugs and therapeutic antibodies, respectively and, when available, 3D renderings of drug-target interactions.

ExpertPath and Immunoquery

Inspirata has established a reseller agreement with Elsevier to include its diagnostic decision support systems in its Diagnostic Cockpit.

ExpertPath™ provides pathologists with instant access to the collective clinical experience and knowledge of renowned sub-specialists in every field of anatomic and clinical pathology.

ImmunoQuery® is the definitive expert and evidence-based decision support system for immunohistochemistry. The ImmunoQuery database is fully referenced with abstract access.

 

Diagnostic Aids

Digital pathology goes far beyond the conversion of glass slides to a digital media. Among the many benefits available with a digital pathology workflow is that algorithms can be run on the image features of the digitized histology slide to gain massive amounts of actionable data. Digital pathology also can decrease the time and cost for diagnosis by giving pathologists tools that automate manual and time-consuming tasks.

Applying our deep experience in image analytics, Inspirata is extracting and quantitating relevant image-based information to build a pipeline of detection, diagnostic, prognostic and theragnostic algorithms and assays. These assays will arm pathologists with new insights that will enable them to better expedite diagnosis, predict cancer progression and patient responses to therapies.

 

Informed Detection

Inspirata is developing a suite of digital pathology algorithms that detect and highlight unusual cell structures and other morphological abnormalities. This pre-screening process is called Informed Detection and can be used to triage the case list as well as assist in directing the pathologist’s eye to potential malignancies quickly thus enabling more rapid case review. The premise is that the less time pathologists spend searching for cancer cells, the more they can focus on what they do best, which is diagnosing the disease.

Pre-screening digital pathology algorithms pinpoint areas of potential malignancy.

  • Prescreening algorithms can identify areas of potential malignancy on lymph nodes helping to minimize search time and maximize diagnostic effort.

Pathologists can zoom into areas on the image that the digital pathology algorithm has pre-screened.

  • As pathologists zoom into regions identified by Informed Detection more detail is available.
Directed Review
mitoSĒK™

Inspirata has developed an innovative screening tool called mitoSĒK that identifies all high-likelihood mitotic figures at intermediate and high-power magnifications. mitoSĒK transforms the time-consuming manual process of counting mitotic figures to a directed review of the computer-detected mitotic figures. A directed review is far more efficient and far less fatiguing for the pathologist.

The pathologist marks a single mitotic figure and then the algorithm finds all similar areas on the entire whole slide image.

  • mitoSĒK™ is a first-pass screening tool that identifies all high-likelihood mitotic figures at intermediate and high-power magnifications, thereby reducing pathologist fatigue.
 histoSĒK™

Laser capture microdissection is an increasingly important pre-analytical step in the diagnostic protocol of many precision medicine tumor analysis protocols. Inspirata’s innovative histoSĒK tool depicts spatial colocation of tumor foreground, while excluding background stroma (an important requirement for next-generation sequencing variant detection, where signal to noise ratio is an issue). It offers an efficient and rapid assist for the pathologist by identifying all tumor areas, thereby generating a gating mask that is usable by contemporary Laser Capture Microdissection instruments.

The pathologist marks a single area of tumor and the algorithm will find those areas, while excluding background stroma.

  • histoSĒK™ automatically identifies and quantifies targeted histology regions. Use cases include microdissection, necrotic area quantification or tumor burden measurements.

Prognostic and Predictive Assays

Increase Diagnostic Accuracy with novel prognostic and predictive assays
Inspirata’s cancer assays, much like popular genomic assays, provide prognoses and predict patient responses to therapies. Our initial product, which is the Image-based Risk Score (IbRiS), uses sophisticated computer algorithms to extract quantitative, morphometric measurements from digitized breast tissue, then analyzes these measurements using a complex classifier that results in a risk score of the likelihood of cancer recurrence and the patient’s response to hormonal therapy.

Source:
Ganesan, S., et al. “Computerized Histologic Image-Based Risk Score (IbRiS) Classifier for ER+ Breast Cancer.“
Cancer Research 69.24 Supplement 3 (2009).

Genome Sequencing for a Specific Signature

Gene sequencing is costly and time consuming.

  • Destroys the tissue
  • Expensive
  • Takes weeks for results
  • Limited global availability
Histology-based for Aggressive Phenotype

Algorithms can find aggressive phenotype faster and cheaper than sequencing.

  • Non-destructive
  • Local CLIA lab
  • Far less expensive
  • Hours versus weeks
  • Available globally
  For research purposes only
Our Partnerships

Learn how Inspirata delivers on the promise of digital pathology through partnerships.

Learn More
White Paper

Read Dr. Metin Gurcan’s White Paper regarding the lessons learned from radiology.

Read Now
Events

Learn more about where Inspirata has visited, and where you can find them next

Learn More